BBC vs NHF

Virtus LifeSci Biotech Clinical Trials ETF

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

NexPoint Strategic Opportunities Fund

NexPoint Strategic Opportunities Fund is a closed ended balanced mutual fund launched by Highland Capital Management, L.P. It is managed by Nexpoint Advisors, L.P. The fund invests in the fixed income markets of the United States. It invests in companies across broadly diversified sectors to construct its portfolio. The fund typically invests in senior loans, secured and unsecured floating and fixed rate loans, bonds, debt obligations of stressed, distressed, and bankrupt issuers, mortgage-backed securities, asset-backed securities, and collateralized debt obligations with a primary focus on below investment grade debt and equity securities. It employs a quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Dow Jones Credit Suisse Hedge Fund and the HFRX Global Hedge Fund. It was formerly known as NexPoint Credit Strategies Fund. NexPoint Strategic Opportunities Fund was formed on June 1, 2006 and is domiciled in the United States.